08 September 2011
St Jude Medical is confident that its Genesis peripheral nerve stimulation (PNS) therapy, which is now CE marked for treating chronic migraine, will play a significant role in driving the company's future growth. This is in spite of uncertainty ...
23 June 2011
A pivotal US trial of the Genesis neurostimulator, a therapy for chronic migraine developed by St Jude Medical, has missed its primary endpoint. The results are likely to hinder St Jude's chances of gaining FDA approval and eventual US ...
11 January 2011
NervoStim, an auto-targeting neurostimulation device developed by Israeli firm Nervomatrix for the treatment of lower back pain, has received 510(k) clearance from the US FDA. The system comprises a scanner that identifies the areas responsible for ...
06 January 2011
Boston Scientific has purchased deep brain stimulation (DBS) expert Intelect Medical in a bid to grow its market share in the neuromodulation space.
Intelect is developing the GUIDE DBS programming system, which it claims is the first system of its ...
12 October 2010
The US FDA has granted a humanitarian use device approval for Synapse Biomedical's Neurx diaphragm pacing system (DPS) in amyotrophic lateral sclerosis (ALS). The device can be used to simulate a breathing motion in ALS patients who have ...
